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to PEG worldwide has become quite elevated and the pro-
longed follow-up allows now to deal quite satisfactorily 
with many clinical issues including major safety issues, 
such as the concerns about possible tumour (re)growth 
under PEG. The positive or neutral impact of PEG on glu-
cose metabolism has been highlighted, and the clinical 
experience, although limited, with sleep apnoea and preg-
nancy has been reviewed. Finally, the current concept of 
somatostatin receptor ligands (SRL) resistance has been 
addressed, in order to better define the acromegaly patients 
to whom the PEG option may be offered.
Conclusions PEG increasingly appears to be an effective 
and safe medical option for many patients not controlled by 
SRL but its use still needs to be optimized.
Abstract 
Background In 2007, we published an opinion document 
to review the role of pegvisomant (PEG) in the treatment of 
acromegaly. Since then, new evidence emerged on the bio-
chemical and clinical effects of PEG and on its long-term 
efficacy and safety.
Aim We here reviewed the emerging aspects of the use 
of PEG in clinical practice in the light of the most recent 
literature.
Results The clinical use of PEG is still suboptimal, con-
sidering that it remains the most powerful tool to control 
IGF-I in acromegaly allowing to obtain, with a pharma-
cological treatment, the most important clinical effects in 
terms of signs and symptoms, quality of life and comor-
bidities. The number of patients with acromegaly exposed 
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Introduction
Acromegaly is a rare chronic disease caused by growth 
hormone (GH) hypersecretion, which is due in more 
than 95% of cases to a GH-secreting pituitary adenoma. 
This hypersecretion of GH and the associated elevated 
IGF-I levels result in increased morbidity and mortality. 
Surgery is in general the first treatment modality, but it 
is not always successful, as the majority of the patients 
have a macroadenoma which is often invasive. Medical 
treatments include somatostatin receptor ligands (SRL), 
dopamine agonists, and pegvisomant (PEG), a genetically 
engineered GH-receptor antagonist [1–3]. Octreotide and 
lanreotide, especially in their long-acting formulations, 
are the most widely used SRL to treat acromegaly; they 
have shown to normalize GH and IGF-I levels in about 
half of patients and reduce tumor mass in a considerable 
proportion of patients [4, 5]. More recently, the multi-
receptor-targeted SRL pasireotide has shown, in Phase 
III clinical trials, to achieve better biochemical disease 
control than octreotide LAR, but to be associated with a 
greater frequency and degree of hyperglycemia and dia-
betes mellitus [6, 7].
PEG has a unique mechanism of action, antagoniz-
ing endogenous GH at the GH receptor level and thereby 
lowering IGF-I production and ameliorating the clini-
cal features associated with acromegaly. In the case of 
PEG, serum IGF-I is the sole biomarker of drug efficacy 
[1, 2, 8]. PEG has been shown to control acromegaly in 
60–90% of patients across several clinical trials [9–18]. 
In Europe, PEG was approved in 2002 for patients treated 
with neurosurgery and/or radiotherapy and not controlled 
by other medical treatments, who may represent up to 
40% of acromegalic patients [19], and since then it was 
shown to effectively control IGF-I secretion in many of 
these subjects [20].
In 2007, we published an opinion document to review 
the role of PEG in the treatment of acromegaly [21]. 
Since then, new evidence emerged on the biochemical 
and clinical effects of PEG and on its long-term efficacy 
and safety. Therefore, we here propose an updated review 
focusing on the emerging aspects of the use of PEG in 
clinical practice in the light of the most recent literature. 
Although combination therapy is currently not included 
in the PEG label, this review will consider also articles 
where PEG was administered in combination with SRL, 
since this approach is sometimes used in the clinical 
practice.
Biochemical outcome
The most recent guidelines recommend IGF-I measurement 
as the effective biomarker of PEG efficacy [1, 2]. However, 
the lack of a shared standardization, the use of different 
antibodies, and interferences due to binding proteins ham-
pers the comparison of the results obtained with different 
commercial IGF-I assays [22]. In addition, population and 
age-specific normal ranges are rarely provided even by lab-
oratories of secondary and tertiary referral centers, despite 
this had been strongly recommended [2, 23]. For these rea-
sons, we believe that it is crucial to monitor disease activity 
in each patient using the same IGF-I assay throughout the 
treatment period.
PEG normalizes IGF-I levels in the majority of patients. 
In pivotal trials, IGF-I normalization was achieved in up to 
95% of patients resistant to SRL treatment [9, 24, 25]. In 
more recent studies, in the real life setting, the rate of dis-
ease control acromegaly was lower, not exceeding 65–70% 
[13, 26–28]. This lower than expected efficacy, observed 
especially in retrospective studies, could be explained by an 
inadequate dose titration of the drug, poor compliance to 
daily injections, selection bias of patients recruited in clini-
cal trials in terms of disease activity and drug responsive-
ness, or technical problems related to IGF-I assay, while 
a true “biochemical resistance” to PEG cannot be ruled 
out yet [29]. Recently, a comparison between secondary 
and tertiary referral centers, identified on the basis of the 
number of acromegalic patients treated with PEG, failed 
to demonstrate significant differences in IGF-I normaliza-
tion rates [30]. According to a recent study, the response 
to PEG as second line medical therapy can be predicted on 
the basis of patient’s age, BMI, and baseline IGF-I levels, 
but not of subjective symptoms [28]. Accordingly, PEG 
starting dose should be higher and dose titration more rapid 
in younger patients, in the obese subjects and in those with 
a worse endocrine profile [31, 32]. Previous studies also 
showed that IGF-I normalization requires lower doses in 
male than in female patients, and in irradiated compared 
to non-irradiated cases [17, 26, 33]. On the other hand, an 
appropriate PEG dose titration up to the maximum allowed 
dosage was shown to normalize IGF-I levels in up to 90% 
of cases, even in the real life setting [34]. It may be con-
cluded that, although the maximum authorized dosage 
is 30  mg daily, there is evidence that some patients may 
respond to doses of 40 mg daily and it can be hypothesized 
that selected cases may respond to even higher doses [34].
PEG exhibits a favorable effect on the glycemic profile 
and can be useful in acromegalic patients with diabetes 
mellitus [21]. However, the rate of IGF-I normalization is 
reduced in patients with diabetes mellitus (64% in diabetic 
vs 75% in non-diabetic patients), and higher PEG doses 
are necessary to control the disease [35]. Possibly, it can 
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be speculated that hyperinsulinism may cause an increased 
expression of hepatic GH receptors, which in turn may 
need higher doses of PEG to be saturated [36].
Data concerning the role of the GH-receptor truncated 
variant (d3GHR) in the biochemical response to PEG are 
controversial. Initial studies reported a better efficacy of the 
drug in patients with d3GHR as compared with those with 
full-length receptor [37, 38]. However, these data were not 
confirmed by subsequent studies, both using PEG alone 
and in combination with SRL [19, 39]. A significant role 
for d3GHR in the biochemical monitoring of acromegaly 
after surgery is also debated [40–42].
Serum GH levels are not a useful marker of PEG effi-
cacy and should not be measured during the treatment, 
because of the cross-reactivity of the drug with endogenous 
GH in commercial GH assays. However, it has been spec-
ulated that a sudden GH increase during PEG treatment 
could indicate pituitary tumor growth [43].
Global clinical effects
Effect on pituitary tumor size
Much attention has been paid to a possible increase in 
tumor size associated with PEG treatment, but also some-
times under SRL treatment, even though no causal rela-
tionship has been established [44]; however, since tumor 
enlargements are detected increasingly often thanks to 
modern techniques, higher consideration should be given to 
the actual clinical relevance of such enlargements.
Data on tumor volume outcome in patients treated with 
PEG alone or in combination with SRL are discordant and 
widely discussed. Some long-term evaluations reported an 
increased tumor size during PEG in 5–7% of patients [45]. 
In the Italian ACROSTUDY patients, according to MRI at 
local centers (data available for 249 patients), a decrease 
in tumor volume was reported at least once in 13.7%, an 
increase in 8.8%, and both increase and decrease in 6.4%, 
in different treatment phases. Bianchi et  al. [46] observed 
that none of 35 patients under PEG alone showed signifi-
cant tumor growth, whereas in one case, MRI documented 
progressive shrinkage of the adenoma, which was no longer 
detectable after 6  years of treatment. In the same study, 
among the 27 patients treated with PEG in combination 
with SRL, a significant growth (>25%) of the residual 
adenoma tissue occurred in one case. This patient had from 
the beginning a very aggressive disease that was difficult if 
not impossible to control, and, when the tumor enlargement 
was noted, was receiving PEG 40  mg/day plus lanreotide 
ATG 120 mg every 4 weeks.
Tumor growth may be observed during the first year of 
treatment with PEG and may prevalently reflect the disease 
natural history or the consequence of SRL discontinuation 
(rebound phenomenon) [47]. Absence of previous irra-
diation and shorter duration of SRL therapy before PEG 
were associated with increased risk of tumor growth [45]. 
Changes in tumor size seem not to correlate with IGF-I 
levels [48]. Optimal use of PEG with respect to tumor size 
should take into account the history of the adenoma in 
terms of aggressiveness and invasiveness, previous tumor 
response to treatments including SRL and tumor volume at 
treatment start [45].
Despite the few reports of increase in tumor size during 
PEG treatment, there is no clear evidence that PEG may 
directly promote tumor growth [47]. Due to the interper-
sonal variability in pituitary, MRI reading by a single neu-
roradiologist of all available images before and during PEG 
therapy is recommended to avoid misinterpretations.
Effect on clinical symptoms and signs, and on quality 
of life
Recent improvement in the medical treatment of acro-
megaly has resulted in better biochemical disease control 
[49–51]. Normalization of both GH and IGF-I levels was 
demonstrated to restore normal life expectancy in acromeg-
aly patients. However, biochemical control does not neces-
sarily relieve all symptoms [52, 53]. To quantify the symp-
toms and the perceived health in patients with acromegaly, 
the Patient-Assessed Acromegaly Symptom Questionnaire 
(PASQ) and the Acromegaly Quality of Life Questionnaire 
(AcroQoL) have been developed [52–54]. In particular, the 
PASQ score is a disease-specific tool that rates five features 
of acromegaly: headache, excessive perspiration, arthralgia, 
fatigue, and soft tissue swelling [52]. On the other hand, 
the AcroQoL questionnaire contains 22 items divided into 
two scales, one evaluating physical features and the other 
assessing psychological aspects [53, 54]. The use of these 
questionnaires may improve clinical evaluation of thera-
peutic interventions, and identification of patients who pos-
sibly require further treatment. Both treatments with SRL 
and PEG showed to be effective in reducing acromegaly 
signs’ and symptoms’ total scores, and improving health-
related quality of life (QoL) [55–57]. However, in patients 
with more severe disease (IGF-I ≥ 2xULN), a trend toward 
greater improvements of PASQ and AcroQoL scores was 
observed with PEG compared with octreotide LAR [57]. 
On the other hand, a lower convenience score was observed 
in patients treated with PEG and evaluated by the Treat-
ment Satisfaction Questionnaire for Medication (TSQM), 
that may be explained by daily injections [58].
PEG therapy was widely demonstrated to be effec-
tive and safe in acromegalic patients, improving clinical 
symptoms and systemic complications [24, 26, 27]. In 
fact, Trainer et al. reported significant decreases in mean 
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patient-assessed symptom scores, including soft tissue 
swelling, degree of perspiration and fatigue, as well as in 
the mean sum scores of all five PASQ items, in patients 
treated with 15 or 20  mg of PEG per day [24]. Subse-
quently, many other studies [25, 59–61] have demon-
strated a significant improvement in acromegaly-related 
QoL, and clinical signs and symptoms in patients treated 
with PEG in monotherapy or in combination with SRL. 
However, the improvement was observed in some but not 
all measures of perceived health or QoL scores. In par-
ticular, pain syndrome, joint complaints, and persistent 
headache seem to persist regardless of type of therapy 
and/or biochemical control [24, 52]. A possible explana-
tion for the different responsivity of symptoms to PEG 
therapy may lie in the nature of symptoms themselves 
[52]. Skin manifestations, such as perspiration, soft tissue 
swelling or numbness, caused by an increase in extracel-
lular volume, edema, dermal glycosaminoglycan accumu-
lation or increased vasoconstriction, are usually rapidly 
alleviated when GH and IGF-I levels are controlled [52, 
62]. Conversely, joint pain may rather reflect chronic and 
irreversible changes [63, 64], so that biochemical control 
per se may not be sufficient to alleviate them, whereas 
headache may better respond to centrally active drugs 
like SRL [65]. For these reasons, additional pain treat-
ment may be needed to relieve these symptoms.
Overall, 11 independent studies [9, 14, 24–26, 31, 
33, 52, 59, 60, 66] specifically focused on headache in 
acromegalic patients on PEG either as monotherapy or 
in combination with SRL. Treatment with PEG has been 
generally reported to negatively impact on headache in 
acromegalic patients, although not significantly. Actu-
ally, the headache score at PASQ was found slightly and 
not significantly impaired in several studies [31, 52, 59]. 
In another study, the headache score in patients on PEG 
monotherapy was not significantly higher than that of 
patients on combined SRL and PEG treatment [60]. In 
patients receiving PEG monotherapy, headache has been 
described in a widely variable percentage, ranging from 
2% [14, 26] to 40.7% [66]. However, the prevalence of 
severe headache leading to definitive treatment discontin-
uation ranged from 1.2% [24] to 28.6% [31]. Noteworthy, 
the association between worsening of headache score and 
increase in tumor size while on PEG therapy is still to be 
fully elucidated. Two different studies have reported dis-
cordant results, with a correlation between worsening of 
headache and increase in tumor size in the first study [66] 
but not in the second one [33]. Curiously, in a study [25] 
comparing long-term therapy with PEG alone, PEG com-
bined with octreotide LAR, and octreotide LAR alone, 
headache was reported only in patients on octreotide 
LAR monotherapy and was related to the disease state.
Taken altogether, these data suggest that the normaliza-
tion of IGF-I may induce an improvement in most acromeg-
aly-related symptoms and QoL. However, normalization of 
clinical picture from the patient’s perspective not always is 
obtained, and further studies are needed to investigate the 
clinical impact of treatment with PEG alone and combined 
with SRL in larger series of patients.
Effect on comorbidities
Glucose and lipid metabolism
In acromegaly, abnormal glucose tolerance, hyperinsuline-
mia, and diabetes mellitus are frequently observed; these 
abnormalities contribute to the increase in cardiovascular 
morbidity and mortality of the disease. In particular, GH 
excess increases glucose production through the hyper-
stimulation of lipolysis, which provides free fatty acids 
(FFAs) and glycerol as metabolic substrates, and inhibits 
insulin-induced suppression of hepatic gluconeogenesis 
[67, 68]. All these effects have a negative impact on insu-
lin action, reducing insulin sensitivity [68]. Treatment of 
acromegaly may influence glucose metabolism in different 
ways. It is known that SRL inhibit insulin secretion, induc-
ing an unpredictable impact on glucose homeostasis [68]. 
This effect may potentially impair glucose homeostasis in 
acromegaly, especially in patients with pre-existing glucose 
intolerance or type 2 diabetes. Indeed, there is evidence 
that currently available SRL, lanreotide autogel (ATG), and 
octreotide long-acting release (LAR) may have an overall 
marginal clinical impact on glucose homeostasis in this 
setting [69], even when used at high doses [70]. However 
sometimes, a clinically significant deleterious glycometa-
bolic effect may be observed in some patients treated with 
conventional SRL, especially when acromegaly is not bio-
chemically controlled by the treatment and high doses of 
analogs are administered (70).
Pasireotide, a new somatostatin receptor ligand that has 
been recently approved for the treatment of acromegaly, 
binds with higher affinity than octreotide and lanreotide to 
somatostatin receptor subtype 5, which is highly expressed 
in pancreatic β cells and modulates insulin secretion [71]. 
Studies performed in healthy volunteers showed that pasir-
eotide inhibited insulin secretion and incretin response, 
with minimal inhibition of glucagon secretion and no 
impact on insulin sensitivity [72]. In acromegaly, pasire-
otide was shown to cause hyperglycemia and diabetes more 
frequently than octreotide LAR, even in patients with bet-
ter-controlled acromegaly [73]. Conversely, PEG therapy 
has been reported to have more favorable effects on glucose 
homeostasis than conventional SRL [29, 74] by improving 
insulin sensitivity and endogenous glucose production rate, 
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reflecting predominantly hepatic glucose production, while 
decreasing overnight FFA levels [75].
Several studies have demonstrated that PEG, used as 
monotherapy, induces a significant decrease in fasting glu-
cose levels also in patients with diagnosed diabetes mel-
litus and impaired glucose tolerance (IGT); there is also 
evidence of an improvement in glucose tolerance and a 
decrease in HbA1c levels [76, 77]. A positive impact of 
PEG on peripheral insulin sensitivity has also been dem-
onstrated, by a significant improvement at the short insulin 
tolerance test [14], and at the hyperinsulinemic euglycemic 
clamp [78, 79] but not when using the homeostatic model 
assessment. Conversely, the effect of PEG on FFAs is still 
controversial. Recent studies failed to demonstrate a reduc-
tion in FFAs, whereas previous papers [79, 80] reported a 
significant reduction in serum FFAs after successful PEG 
treatment, explaining, at least in part, the improvements 
in hepatic insulin sensitivity. However, it is important to 
note that a substantial proportion of patients in those stud-
ies were completely or partially resistant to SRL; therefore, 
improvement in glucose metabolism might be rather due 
to better biochemical control and to the reverted inhibitory 
effect of the SRL on insulin secretion.
These findings suggest that in patients resistant to SRL 
with uncontrolled diabetes mellitus or worsening hyper-
glycemia, PEG monotherapy may be the first medical 
option, since it may allow to reach the combined objec-
tive of improving both biochemical control and glucose 
metabolism.
Variable results were observed on lipid metabolism after 
PEG. An increase in total and LDL cholesterol (LDLc), 
with unchanged triglyceride levels and a significant decline 
in lipoprotein (a) levels was observed [51]. Small, uncon-
trolled studies reported no change of lipid profile during 
PEG therapy. Kuhn et  al. found that long-term treatment 
with PEG seems to be associated with minimal increase in 
plasma LDLc [81].
Data on changes in BMI during treatment with PEG 
are scarce and conflicting: some studies have shown an 
increase in BMI [82, 83] while others showed no change 
[84, 85]. Overall, however, the data suggest an increase in 
fat mass [86], particularly intra-abdominal fat mass [87], 
and also a decrease in lean body mass and extracellular 
water, which might explain the neutral effect of PEG on 
BMI in some studies [81].
Cardio‑respiratory system
In acromegalic patients highly resistant to SRL, long-term 
(at least 18 months) treatment with PEG induced a signifi-
cant reduction of cardiac mass. Particularly, in a retrospec-
tive study, Kuhn et  al. evaluated, by echocardiography, 
the long-term (up to 10  years) impact on cardiovascular 
comorbidity in a series of 42 acromegalic patients treated 
with PEG alone (19 cases) or in combination with SRL 
and/or cabergoline (23 cases). The authors showed that 
20 ± 16  months after PEG introduction, left ventricular 
ejection fraction (LVEF) improved significantly in patients 
with systolic dysfunction and decreased or normalized in 
acromegalic patients with a hyperkinetic syndrome [80]. 
Moreover, a decrease in LV mass index was reported in 
patients with most severe LV hypertrophy. Treatment with 
PEG also exerted beneficial effects on rhythm disorders and 
hyperkinetic syndrome, carotid arteries wall thickness, and 
blood pressure, particularly in terms of diastolic values, in 
hypertensive patients [51].
Respiratory disorders are frequent complications in 
patients with acromegaly, with a potential impact on both 
morbidity and mortality [88]. The most frequent respira-
tory complication of acromegaly is the obstructive sleep 
apnoea syndrome (OSAS) with a prevalence up to 80% 
of patients at diagnosis [88–90]. The pathogenesis of the 
OSAS in acromegaly is complex, including systemic as 
well as local effects of GH and IGF-I excess, such as altera-
tions in the facial bone structure, soft tissue swelling of the 
upper airways, and macroglossia. The relationship between 
activity of the disease and severity of OSAS in acromegaly 
is controversial: studies have shown either a positive or no 
correlation between serum GH and IGF-I levels and indices 
of sleep apnoea [90–93]. The impact of medical therapies 
for acromegaly on the prevalence and the severity of OSAS 
is not clear, although some studies reported an improve-
ment of OSAS severity after biochemical control of disease 
was achieved by SRL [94, 95].
The effect of PEG on respiratory complications of acro-
megaly has been evaluated in two studies including a small 
number of patients [81, 96]. In one study, twelve subjects 
with uncontrolled acromegaly under SRL were evaluated 
using polysomnography and MRI of the tongue before and 
6 months after the introduction of PEG [96]. In that study, 
the achievement of biochemical control obtained by PEG 
was associated with an overall improvement of the indices 
of apnoea [i.e., reduction of the severity of sleep apnoea 
and of the apnoea-hypopnea index (AHI)] and with a sig-
nificant shrinkage of the tongue volume [96]. In addition, 
the authors reported a correlation between IGF-I levels and 
tongue volume, whereas AHI improvement did not corre-
late with the decrease in IGF-I levels, nor with BMI, BMI-
adjusted tongue volume or age. The other assessment of the 
effect of PEG on sleep apnoea was conducted in a subset 
of twelve acromegalic subjects included in a retrospective 
single-center study on the effects of the treatment with the 
GH-antagonist, alone or associated with other treatments, 
on the systemic comorbidities of acromegaly [81]. The 
results of this study were consistent with those of the previ-
ous study, showing a significant improvement of AHI and a 
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reduction of the severity of the sleep apnoea after the intro-
duction of PEG and the improvement of the biochemical 
control of acromegaly.
Overall, the results of these two studies suggest a posi-
tive impact of PEG therapy on the severity of apnoea; 
larger prospective studies are needed to evaluate the impact 
of PEG on the incidence of OSAS.
Bone
In acromegaly, there is an increase in the risk of verte-
bral fractures [97], which is not necessarily associated 
with reduced bone mass [98], but rather with an increased 
bone turnover [99] that was normalized after 6 months of 
PEG treatment [100]. Long-term treatment with PEG also 
induced a significant increase of bone mineral density in 
active acromegaly [101]. Although PEG use was weakly 
associated with an increased rate of fractures, this has been 
attributed to global increased severity of the disease in 
treated patients [102].
Safety
Liver test abnormalities
A generally mild and transient liver transaminase levels 
elevation (LTLE) was reported in about 5–8% of patients 
in surveillance studies, the highest percentages being gen-
erally [45, 48] but not always [46] observed when PEG 
was combined with SRL. Different risk factors for devel-
oping LTLE have been hypothesized, such as type 2 dia-
betes mellitus, the common polymorphism (UGT1A1) of 
Gilbert’s syndrome, and male sex [47]. Of the 341 acro-
megaly patients included in the Italian ACROSTUDY, liver 
test abnormalities (>3 × ULN of ALT and AST, >1 × ULN 
of ALP, bilirubin or GGT) were observed in 27 patients. 
In three patients (0.9%), a clinically significant increase of 
transaminases (>5 × ULN of ALT or AST) was reported 
after 3 months of PEG therapy, but levels normalized spon-
taneously or after PEG withdrawal (data available for 320 
cases) [27].
Lipodystrophy
Injection-site reactions, reported with a frequency up to 
11%, were generally mild, erythematous, self-limited, and 
did not require treatment [26]. Lipodystrophy, a localized 
disorder of adipose tissue resulting in depressed skin areas 
(lipoatrophy) or areas of fat overgrowth (lipohypertrophy), 
has been observed during PEG therapy due to local GH 
lipolysis inhibition [18, 26, 103–106].
In 1288 patients of the ACROSTUDY, lipodystrophy 
was reported as a minor side effect with a very low preva-
lence (1.4%) [26]. However, a recent multicentre retrospec-
tive study involving 19 Spanish centers [18] reported lipo-
dystrophy development in 15% of patients (15/97), mostly 
females. Fourteen patients had lipohypertrophy and one 
lipoatrophy. When all possible treatment associations were 
analyzed, only the triple association of SRL, cabergoline, 
and PEG was related to a higher incidence of lipodystrophy 
(42 vs 11%, p = 0.018). Interestingly, lipodystrophy did not 
depend on PEG dose, but there was a significant relation-
ship between the grade of lipodystrophy and escape from 
PEG, defined as loss of biochemical control in a patient 
who was previously controlled (p = 0.019). This obser-
vation suggests that the presence of lipodystrophy might 
influence the response to treatment. The female prevalence, 
observed also in previous studies [103–106], might be due 
to a greater accumulation of subcutaneous adipose tissue or 
to a gender-specific adipocyte response. Only few patients 
discontinued treatment due to lipodystrophy. Generally, 
lipohypertrophy regressed in all patients after medication 
was discontinued.
Overall, in patients receiving PEG, injection sites should 
be monitored for early signs of lipodystrophy and patients 
should be trained to frequently change the site of injection.
Reproductive system and pregnancy
In women with acromegaly, reproductive disorders, includ-
ing menstrual abnormalities, galactorrhoea, and decreased 
libido, are commonly reported, occurring in 40–80% 
of patients [107–110]. In particular, women with acro-
megaly often present with menstrual irregularity, mainly 
oligo-amenorrhea, associated with anovularity and infer-
tility. Hypopituitarism or a direct action of GH and IGF-I 
excess on the pituitary–gonadal axis or the co-existence 
of hyperprolactinemia due to mass effect or to prolactin 
hypersecretion by the tumor have been proposed as poten-
tial mechanisms for the impairment in gonadotropin secre-
tion, leading to ovarian dysfunction and consequent infer-
tility [108–110]. Moreover, IGF-I excess was found to be 
associated with polycystic ovarian syndrome (PCOS) or a 
PCOS-like phenotype in 50% of acromegalic women with 
newly diagnosed or uncontrolled disease, despite previous 
treatment with surgery or SRL, particularly in those with 
small tumors and intact gonadotropinaxis [111]. However, 
few data are to date available about the fertility outcome 
in acromegalic women [112–117], since approximately 100 
pregnancies have been described in literature [112]. Conse-
quently, the management of acromegaly during pregnancy 
has to be precisely defined and the benefit-to-risk profile of 
the different treatment options need to be evaluated at the 
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single patient level due to the limited data available on their 
safety and efficacy.
Generally, in patients with GH-secreting pituitary micro-
adenomas or small tumor remnants, medical therapy can 
be safely withdrawn shortly after pregnancy confirmation 
[112, 117], carefully monitoring clinical symptoms of 
potential tumor enlargement (visual field); whereas in those 
with macroadenomas at high risk of tumor growth, medical 
therapy can be maintained throughout the pregnancy [112, 
117]. Dopamine agonists (DA) and SRL represent the treat-
ment of choice in acromegalic women during pregnancy, 
since the clinical cases reported so far have demonstrated 
that the use of these drugs in pregnant patients did not 
affect pregnancy course and fetal development [112, 113, 
116, 118, 119].
The safety of PEG in pregnancy, as well as its potential 
fetal effects, is yet to be assessed. Early embryonic devel-
opment and teratology studies in pregnant rabbits have 
failed to demonstrate any evidence of teratogenic effects at 
subcutaneous doses of 1, 3, and 10 mg/kg/day. At the dose 
of 10 mg/kg/day, a slight and reproducible increase in post-
implantation loss was observed. However, this dose is ten 
times the maximum therapeutic dose, based on body sur-
face area [120]. Moreover, it has to be considered that ani-
mal studies are not always predictive of human responses 
to pharmaceutical agents [120]. Nevertheless, PEG cannot 
be recommended in human pregnancies. So far, only two 
cases of women that conceived during PEG therapy were 
reported in detail [120, 121] and a recent analysis [122] 
identified 35 unique pregnancies from the Pfizer’s Global 
Safety Database including pregnancies during PEG expo-
sure. Qureshi et al. [120] reported the first case in the litera-
ture of a 29-year-old woman with previously uncontrolled 
acromegaly, that conceived at her first cycle of in  vitro 
fertilization and intra-cytoplasmic sperm injection, after 
IGF-I normalization during PEG monotherapy. PEG was 
immediately discontinued. Pregnancy was complicated by 
gestational diabetes and deterioration of visual field, but 
no tumor enlargement was observed. Conservative man-
agement with elective cesarean section was performed 
at 38  weeks of gestation and a healthy boy was deliv-
ered. Subsequently, Brian et al. [121] reported a case of a 
26-year-old female with uncontrolled acromegaly, despite 
surgery, DA, and SRL therapy. After IGF-I normalization 
with PEG monotherapy, the patient conceived and contin-
ued PEG therapy throughout pregnancy. The PEG dose was 
increased during pregnancy up to 25 mg/daily. No compli-
cations were reported during pregnancy, an elective cesar-
ean was performed at 40 weeks of gestation and a healthy 
girl was delivered. Interestingly, maternal and fetal PEG 
levels were also evaluated in this woman. Maternal PEG 
levels were consistent with a 25-mg daily dosage, whereas 
fetal PEG levels were minimal and near the range detected 
in untreated acromegalic patients. The GH variant levels 
in maternal and cord blood were within the normal ranges, 
and PEG levels in breast milk were below the lower limit of 
quantification of the assay and similar to those found with 
the same assay in milk samples from normal mothers.
Van der Lely et  al. [122] recently reported the largest 
series of data available to date, which seem not to suggest 
adverse consequences of PEG on pregnancy outcome in 
acromegaly. In particular, they reviewed data on 35 preg-
nancy outcomes of acromegalic patients exposed to PEG 
included in the Pfizer’s Global Safety Database. Of these 
35 pregnancies, 19 were included in the ACROSTUDY. 
Twenty-seven out of 35 pregnancy cases involved maternal 
exposure to PEG and 8 cases involved paternal exposure to 
PEG. A normal newborn was reported in 14 cases; while 
in 4 cases, a live birth was reported, but the outcome of 
the birth was not specified. In nine cases, the fetal outcome 
was not reported. In three cases of maternal exposure that 
reported a normal newborn, PEG was continued through-
out the pregnancy at a mean dose of 12.1 mg/day. In two 
cases a non-PEG-related spontaneous abortion occurred, in 
three cases a cesarean section was performed, and in one 
case a non-PEG-related ectopic pregnancy occurred and in 
three women gestational diabetes developed.
In summary, until now, the available data do not suggest 
adverse effects on pregnancy outcome associated with PEG 
therapy, although the number of pregnancies during expo-
sure to PEG reported in the literature is too small to issue 
any types of indication. For this reason, the use of PEG dur-
ing pregnancy is not recommended unless absolutely clini-
cal necessary (i.e., severe acromegaly-related diabetes, or 
cardio-respiratory complications in SRL-resistant patients). 
The potential fetal effects of PEG are still unknown. In par-
ticular, more studies are needed to evaluate PEG effect on 
fetal growth and possible interference on the placental GH 
activity, since during pregnancy placenta produces human 
GH, that differs from pituitary GH by 13 amino acids [123] 
and displays its biological effect through the same GH 
receptor [124]. PEG therapy during breast-feeding should 
also be avoided as it is unclear whether this drug is excreted 
or not in breast milk.
Resistance to SRL
PEG finds its main indication in patients partially or 
completely resistant to SRL treatment [29, 50]. Some 
clinical and pathological aspects have been proposed to 
be effective in predicting the response to SRL. In par-
ticular, a better response seems to be associated to female 
sex, older age, hypo-intensity in T2 at MRI, high SST2R 
expression, high AIP expression at immunohistochem-
istry, low Ki67 index, a “densely granulated” pattern at 
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electronic microscopy [125, 126]. A partial to absent 
response to SRL is also related to particular genetic alter-
ations as observed in patients bearing AIP gene mutations 
or the newly discovered X-linked acrogigantism [127].
To define the therapeutic efficacy of SRL treatment, 
the effects on both GH/IGF-1 secretion and tumor mass 
are considered, these parameters being generally evalu-
ated after 6–12  months of therapy with both octreotide 
LAR and lanreotide ATG at “conventional” maximal 
doses (i.e., 30  mg/28  days and 120  mg/28 days, respec-
tively) [128, 129]. Current guidelines define biochemi-
cal control as random GH values <1 ng/ml, IGF-I within 
the normal age-specific levels, and GH nadir following 
OGTT less than 1 or 0.4 ng/ml [1, 130].
However, some aspects of the definition of resistance 
to SRL need to be improved. In particular, the limitations 
of this definition so far are tied to the target GH value (1 
vs 2.5 ng/ml), the clinical relevance of a significant tumor 
shrinkage, the use of percentage reductions of GH/IGF-I 
vs absolute values, the improvement of clinical signs and 
symptoms. It is worth noting that a relevant parameter 
to consider in defining a patient as resistant or partially 
responsive is the duration of SRL therapy [131]. This 
aspect turns out to be particularly important because the 
delay between the onset and the diagnosis of acromegaly 
has not been reduced in the last decades [132], and such a 
diagnostic delay requires rapid normalization of both GH 
and IGF-1 secretion to avoid further exposure to elevated 
GH/IGF-I concentrations.
Management of SRL‑resistant patients
A patient with GH/IGF-1 reduction <50% and/or tumor 
mass shrinkage <20–25% may be considered as SRL-
resistant. In this respect, the results obtained after 
6 months seems to be predictive of the long-term efficacy 
of SRL treatment [128]. In particular, it has been pro-
posed that when a patient does not show any biochemi-
cal responses after 6 months of treatment it is advisable 
not to continue with SRL and to switch towards PEG in 
monotherapy. No studies are so far available showing 
the efficacy of both pasireotide and SRL at high doses 
in improving the biochemical response in SRL-resistant 
patients.
In patients bearing pituitary macroadenomas, it 
has been proposed to prolong SRL treatment up to 
12–18  months to evaluate a possible late effect on 
tumor mass independently from the efficacy on hormone 
secretion. In particular, in these patients, a combined 
SRL–PEG treatment might be proposed to normalize 
GH/IGF-1 secretion waiting for a possible delayed SRL 
effect on tumor mass.
Management of patients with a partial biochemical 
response to SRL
A GH/IGF-I reduction >50% without reaching normaliza-
tion is considered according to recent guidelines as a partial 
biochemical response to SRL [51]. In patients with partial 
response to conventional maximal doses of SRL, different 
medical options can be considered.
PEG in monotherapy was shown to effectively con-
trol IGF-I secretion in the large majority of these subjects 
[29], being also often effective in normalizing glucose pro-
file. A recently published study [20] showed that SRL at 
higher doses (i.e., octreotide LAR 60  mg/28  days) were 
effective in normalizing hormone secretion in about 36% 
of acromegalic patients. In a similar setting, pasireotide 
reduced mean GH levels to less than 2.5 ng/mL in 35–45% 
of cases and normalized IGF-I in 15–20% [50]. However, 
while high doses of SRL did not affect glucose metabo-
lism [70], pasireotide induced a negative effect on glucose 
metabolism.
Timing of the switch from conventional SRL
Although 12  months of treatment are traditionally neces-
sary to define a partial resistance to SRL [128], it is con-
ceivable to switch to a different option within 6  months 
from the beginning of SRL if the GH/IGF-I levels remain, 
in absolute terms, well above the target values.
Type of switch
ually the achievement of a complete biochemical control. 
However, in a “patient-oriented” strategy, other elements 
should be considered in the therapeutic decision-making, 
since they may dictate the necessity for a rapid biochemi-
cal correction of the disease or the preference for one or the 
other medical tool or their combination. In particular, the 
absolute values of GH and IGF-I as well as the presence 
and severity of comorbidities and of tumor residues having 
a significant mass effect, therapy costs, and patient compli-
ance should be taken into account when deciding to switch 
to a different therapy.
PEG represents the first choice therapy in patients in 
whom the severity of the disease requires a quick IGF-1 
normalization, through appropriate titration of the drug [27, 
45], as well as in not fully compensated diabetic patients. 
The latest guidelines recognize the relevance of PEG treat-
ment either in monotherapy or in combination with SRL 
because it is highly effective in IGF-I normalization [29, 
51]. PEG in monotherapy was proven to be effective in nor-
malizing IGF-I in up to 88% of patients resistant to SRL 
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[9]. The combination therapy with SRL appears an effec-
tive option in those patients in whom SRL had shown to be 
effective in reducing pituitary tumor mass.
High doses of SRL [20] might be used when the clinical 
situation does not require an immediate normalization of 
GH/IGF-1 secretion, but the percentages of normalization 
are lower than those observed with PEG. In this subset of 
patients, pasireotide might be an alternative option, though 
high-dose SRL should be preferred in those with diabetes 
mellitus.
Conclusions
This review focuses on some emerging aspects of the man-
agement of acromegaly with particular reference to their 
impact on the clinical use of PEG which may be considered 
still suboptimal. In fact, PEG remains the most powerful 
tool to control IGF-I in acromegaly and therefore the medi-
cal treatment through which we can obtain the most impor-
tant clinical effects either in terms of signs and symptoms 
or of quality of life or of comorbidities. The goal for the 
clinician is to offer this treatment option to all the patients 
that are likely to benefit from it and to adequately moni-
tor its clinical and biochemical effects. From the review of 
the most current literature, it appears that the number of 
patients with acromegaly exposed to PEG worldwide has 
become quite elevated and their prolonged follow-up allows 
us to deal quite satisfactorily with many clinical issues, 
including most importantly the safety of the treatment. In 
particular, this review highlights that issues concerning 
the possible tumor (re)growth under PEG have been sig-
nificantly down-played by the recent literature although in 
some patients at high risk in this regard the co-treatment 
with SRL can be considered to further minimize the risk. 
On the other hand, the positive or neutral impact of PEG 
on glucose metabolism has been highlighted as it may indi-
cate PEG as the best medical option in acromegaly patients 
with diabetes mellitus. We have also reviewed some aspects 
of the treatment with PEG which are less frequently dealt 
with, also due to the limited experience available, such as 
sleep apnoea and pregnancy. In this latter case, although 
the very limited published material is reassuring, PEG 
use remains not indicated in acromegaly patients undergo-
ing pregnancy. Finally, in an attempt to adequately define 
all the patients to whom PEG option may be offered, we 
dealt with the current definition of SRL resistance. This 
issue so far has been mainly defined based on biochemical 
and tumor elements; however, we propose to consider other 
aspects that can refine the definition, taking into account 
some literature trends which try to predict response (or no 
response) to SRL and elements that may affect the neces-
sity for the clinician to obtain a rapid and full response to 
treatment. In conclusion, PEG increasingly appears to be 
an effective and safe medical option for many patients not 
controlled by SRL but its use still needs to be optimized.
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